December 2024, Vol 14, No 12
2024 has been a tumultuous year. Every one of our editorials explored a different way that cancer practices faced new challenges to their patients’ access to the care they need and the resources that can ease the emotional and financial burdens of their treatment. Read More ›
Part of my job as a CFO and operations manager is to set the culture for the
staff and the doctors. Read More ›
Approximately 40% of American men and women will be diagnosed with cancer at some point in their lives, with the cost of cancer care in the United States projected to exceed $245 billion by 2030. Read More ›
Natural disasters like hurricanes and wildfires impact access to care for patients with cancer, concluded 2 separate studies that were presented at the 2024 American Society of Clinical Oncology (ASCO) Quality Care Symposium. Read More ›
Patients diagnosed with major diseases, including cancer, often experience financial hardship due to high out-of-pocket medical costs in the United States. Read More ›
Increased access to broadband usage was associated with earlier-stage non-small cell lung cancer diagnosis and with receiving guideline-concordant care in 2020, during the height of the COVID-19 pandemic. Read More ›
Officials with the FDA recently approved the menin inhibitor revumenib (Revuforj; Syndax Pharmaceuticals, Inc.) for relapsed or refractory acute leukemia with a lysine methyltransferase 2A gene translocation. Read More ›
The CD19-directed genetically modified autologous T-cell immunotherapy, obecabtagene autoleucel (Aucatazyl; Autolus Inc.), has been approved for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukemia. Read More ›
Asciminib (Scemblix; Novartis AG) has been approved for use in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. Read More ›
Officials with the Food and Drug Administration have approved zolbetuximab-clzb (Vyloy, Astellas Pharma US, Inc.) Read More ›
This feature examines some of the cutting-edge trials that have been launched throughout 2024 and that are actively recruiting in breast cancer. Read More ›